echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Roche/Regeneron COVID-19 antibody cocktail therapy significantly reduces the risk of hospitalization/death

    Roche/Regeneron COVID-19 antibody cocktail therapy significantly reduces the risk of hospitalization/death

    • Last Update: 2021-03-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Compilenewborn

    Regeneron and its partner Roche have new phase III clinical data to show that they can treat sick patients and protect people who have not been vaccinated.


    REGEN-COV consists of two monoclonal antibodies casirivimab and imdevimab.


    In November 2020, REGEN-COV was granted an emergency use authorization (EUA) by the US FDA.


    But REGEN-COV also faces competition from Eli Lilly's antibody cocktail.


    Roche and Regeneron emphasized the relevance of the latest clinical trial results to protect high-risk populations from COVID-19 and emerging virus variants.


    An investigator of the trial, Suraj Saggar, director of infectious diseases at the Holy Name Medical Center in Teaneck, New Jersey, said in a statement, “Because there are still so many people infected, and recent data show that REGEN-COV is treating The ability of new variants, these data emphasize the need to quickly adopt REGEN-COV as the standard of care to provide high-risk patients with the best opportunity to reduce serious consequences such as hospitalization or death.


    Regeneron said that the company expects REGEN-COV to reach US$260 million in sales in the US market in the first quarter of this year.


    In the cooperation between Regeneron and Roche, Regeneron is responsible for the development and commercialization of the US market, while Roche is responsible for markets outside the US.


    However, given that the supply of vaccines will increase significantly in the next few months, is there still a need for COVID-19 treatments globally? Dr.


    Currently, other clinical trials of REGEN-COV are being conducted around the world, including a Phase 3 trial for the treatment of hospitalized COVID-19 patients in the UK, and a preventive trial in the family members of COVID-19 patients to test REGEN- The therapeutic and protective effects of COV.


    Reference source: Regeneron, Roche COVID-19 antibody cocktail slashes hospitalizations and tackles variants in phase 3

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.